RRRuben Rhoades

Ruben Rhoades

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruben Rhoades has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An unusual trigger for a rare hemolytic anemia: paroxysmal cold hemoglobinuria after shingles and COVID-19

    by Adam G. Mermelstein, Sean P. Reilly, Ruben Rhoades

    Paroxysmal cold hemoglobinuria (PCH) is a rare autoimmune hemolytic anemia that commonly presents as a transient, post-infectious disease mediated by biphasic Donath-Landsteiner antibodies, which bind to red blood cells at cold temperatures but cause hemolysis at core body temperature. PCH is less common in adults but can be a complication of infection or hematologic malignancy. One viral trigger of PCH that has rarely been described is that of primary varicella-zoster virus (VZV). Here, we report the case of a 69-year-old man who developed severe PCH following an episode of shingles, raising the possibility of a temporal relationship between PCH and VZV reactivation. Erythrophagocytosis and rosetting of red blood cells around neutrophils, smear findings commonly seen in PCH, were observed on the patient’s blood smear and aided in our diagnosis. Initial hemolysis testing demonstrated complement component 3-positive, immunoglobulin G-negative direct antiglobulin testing. Donath-Landsteiner testing confirmed a diagnosis of PCH. The patient had a complicated 38-day hospital course that required mechanical ventilation, renal replacement therapy, and extensive transfusions. Notably, the patient was also diagnosed with COVID-19 shortly before the onset of hemolysis, representing a potential alternative trigger or co-trigger to his PCH. Although the clinical timeline is compatible with VZV reactivation triggering PCH, the specific infectious trigger cannot be definitively established. Nevertheless, to our knowledge, this is the first reported case of PCH occurring in temporal association with VZV reactivation rather than primary VZV infection.

  • Hemoglobin: The Ideal Conveyor of Oxygen

    by Sohiel Deshpande, Ruben Rhoades

  • Open Access

    Clinical utility and costs of inpatient hereditary thrombophilia testing following acute VTE: A 5-Year retrospective study

    by Eliakim Munda, Ruben Rhoades

    Hereditary thrombophilia testing is frequently ordered after venous thromboembolism (VTE), despite little evidence of clinical utility and most guidelines cautioning against testing. We conducted a retrospective, observational study of inpatient hereditary thrombophilia testing ordered during a hospital admission for acute VTE between 2019 and 2024. We aimed to characterize patterns of testing results, and costs, and to evaluate whether younger patients and those with unprovoked VTE were more likely to test positive for hereditary thrombophilia. A total of 835 hereditary thrombophilia tests – including those for factor V Leiden, prothrombin G20210A , deficiencies of protein S, protein C, and antithrombin, hyperhomocysteinemia, and plasminogen activator inhibitor-1 excess – were ordered in 220 patients. Overall, 19.6% of results were abnormal, and 45.0% of patients had at least one abnormal result. There was no difference in the rate of positive results among patients with provoked vs. unprovoked VTE (30.7% vs. 34.5%, p = .554) nor patients < 50 vs. ≥ 50 years of age (33.1% vs. 32.4%, p = .912). Only 4/99 (4.0%) patients with an abnormal result had their clinical management clearly changed due to the result. The tests totaled $385,161 USD in institutional charges and $26,029 USD in Medicare fees. Inpatient hereditary thrombophilia testing during admission for acute VTE is low yield, with frequent abnormal results, many of which likely represented false positives, and minimal impact on clinical management with high costs. Graphical abstract


  • Open Access

    An Unusual Complication of Metastatic Colorectal Cancer: Port-Site Hematoma as the First Sign of Bone Marrow Involvement and Disseminated Intravascular Coagulation

    by Michael Predi, Julia Palecki, Jordan Isaacs, Ruben Rhoades

    Disseminated intravascular coagulation (DIC) is a life-threatening condition marked by a spectrum of thrombosis due to activation of procoagulant factors and bleeding due to eventual consumption of these factors. DIC invariably occurs secondary to an underlying condition, including infection, inflammatory conditions, trauma, and malignancies. Treatment of DIC primarily involves treatment of the underlying cause.1 Bone marrow invasion occurs when tumor cells infiltrate the hematopoietic marrow space, displacing progenitor cells and causing cytopenias. This process is distinct from bone metastases, where malignant cells spread to the cortical or trabecular bone, typically causing bone pain, pathologic fractures, or hypercalcemia. Disseminated carcinomatosis of the bone marrow (DCBM) is a particularly severe form of marrow involvement, characterized by widespread and uniform infiltration that can result in profound cytopenias, marrow failure, and DIC.2,3 Cancers most commonly associated with bone marrow invasion include prostate, lung, breast, and gastric malignancies. While gastric cancer rarely metastasizes to bone, it is frequently cited as a malignancy associated with marrow infiltration. In contrast, metastatic colorectal cancer rarely presents with DCBM leading to DIC.4,5 We present a case of a patient with metastatic colon cancer who developed acute anemia due to a large port-site hematoma. Further investigation revealed DCBM, rising carcinoembryonic antigen (CEA) levels, and DIC. In this case report, we outline the clinical course and management of this patient. Additionally, we review published cases of this rare pathology, providing insights into its presentation and clinical implications.

  • Low value of inherited thrombophilia testing among patients with stroke or transient ischemic attack: A three-year retrospective study

    by Shyam Majmundar, Sameep Thapa, Elan S. Miller, Rodney Bell, Robin Dharia, Diana Tzeng, Shaista Alam, Ruben Rhoades


  • Open Access

    Perioperative Outcomes of Patients with Bleeding Disorders Undergoing Major Surgery at an Academic Hemophilia Treatment Center

    by Ruben Rhoades, Zachary French, Amy Yang, Karen Walsh, Douglass A. Drelich, Steven E. McKenzie

    Persons with bleeding disorders (PwBD) are at high risk for bleeding with invasive procedures. However, the risk of bleeding in PwBD undergoing major surgery and outcomes of patients managed perioperatively at a hemophilia treatment center (HTC) are not well described. We performed a retrospective review of surgical outcomes among PwBD undergoing major surgery between January 1st, 2017 and December 31st, 2019 at the Cardeza Foundation Hemophilia and Thrombosis Center in Philadelphia, PA. The primary outcome was postoperative bleeding, assessed according to the ISTH-SSC's 2010 definition. Secondary outcomes included use of unplanned postoperative hemostatic therapy, LOS, and 30-day readmission rate. Results were compared to non-PwBD population from a surgical database, matched for surgery, age, and sex. During the study period, 50 PwBD underwent 63 major surgeries. The most common diagnoses were VWD (64%) and hemophilia A (20.0%). The most common surgical procedure category was orthopedic (33.3%), predominantly arthroplasties. Postoperatively,4.8% of procedures were complicated by major bleeding and 1.6% by non-major bleeding. The mean LOS was 1.65 days, and 30-day readmission rate was 1.6%. In comparison to matched, non-PwBD patients in a national surgical database undergoing the same procedures, study patients had a similar rate of bleeding complications per procedure (5.0% vs 1.04% P = .071, Fisher's exact test). PwBD undergoing major surgeries have low rates of major bleeding when receiving comprehensive care at an HTC. Bleeding and hospital readmission rates were similar to non-PwBD baseline in a large database.


  • Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy

    by Ruben Rhoades, Ron Leong, Jason Kopenitz, Brandi Thoma, Lydia McDermott, Joseph Dovidio, Shannon Barletti, Jerald Z. Gong, Howard T. Massey, Steven E. McKenzie, et al.


  • Open Access

    Development and Validation of Postoperative Venous Thromboembolism risk prediction model

    by Sang Hoon Woo, Ruben Rhoades, Lily Ackermann, Scott W. Cowan, Jillian Zavodnick, Gregary D. Marhefka

    Background: VTE is a serious postoperative complication after surgery with resultant higher morbidity and mortality. Despite years of experience with current risk models, rates continue to be high and more information is needed on individual patient risk in the prophylaxis era. Research Questions: Can we assess the individualized risk of postoperative venous thromboembolism (VTE) for broad categories of surgery? Methods: This study was performed using data from the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) Database. Patient data (n=2,875,190) from 2015-2017 were used for study analysis. Eight predictors were selected for the model: age, preoperative platelet count≥450 (×10 9 /L), disseminated cancer, corticosteroid use, serum albumin ≤2.5 g/dL, preoperative sepsis, hospital length of stay and surgery type. The second model included 7 predictors without hospital length of stay. A predictive model was trained using ACS-NSQIP data from 2015-2016 (n=1,859,227) and tested using data from 2017 (n= 1,015,963). Primary outcomes are postoperative 30-day VTE, including deep vein thrombosis (DVT) and/or pulmonary embolism (PE). Results: VTE occurred in 23,249 patients (0.81%) and 49.9% of VTE occurred after discharge from index hospitalization. The risk prediction model had high AUC (area under the receiver operating characteristic curve) for postoperative VTE of 0.78 (training cohort) and 0.78 (test cohort). Interpretation: This clinical prediction model is a validated, practical and easy-to-use tool to identify surgical patients at the highest risk of postoperative VTE and provide an individualized assessment of risk based on clinical factors and type of surgery. This prediction model may be used as a tool to assess individualized risk of postoperative VTE and promote broader discussion and awareness of the VTE risk during the perioperative period.

  • Primary central nervous system plasmablastic lymphoma in an HIV-positive patient

    by Ruben Rhoades, Jerald Gong, Neil Palmisiano, Onder Alpdogan

    Plasmablastic lymphoma (PBL) is a rare subtype of diffuse large B-cell lymphoma, highly associated with HIV and Epstein-Barr virus (EBV) infections. It commonly presents in extranodal sites, often an oral mass, but reports of primary central nervous system PBL (PCNSPBL) are exceedingly rare. Here, we report on a 33-year-old man with newly diagnosed HIV infection who presented with acute-onset unilateral visual disturbance and was found to have biopsy-proven PCNSPBL. The neoplastic cells displayed a plasmacytoid appearance, with the expression of CD38 and CD138, and were positive for EBV by in situ hybridisation for EBV-encoded RNA. Systemic workup revealed the presence of Kaposi sarcoma, but no evidence of lymphoma. He is currently being treated with high-dose methotrexate, as well as antiretroviral therapy for his HIV infection, and has achieved a complete response.